|
1 Introduction to Precision Medicine and Animal Models |
|
|
1 | (15) |
|
|
2 | (1) |
|
Organization of This Proceedings of a Workshop |
|
|
3 | (1) |
|
What Is Precision Medicine and How Did We Get Here? |
|
|
4 | (2) |
|
Regulation of Precision Medicine |
|
|
6 | (3) |
|
Ethical Considerations of Animal-Based Research |
|
|
9 | (3) |
|
|
11 | (1) |
|
|
12 | (1) |
|
|
12 | (1) |
|
Bioethics, Public Opinion, and Community Advisory Boards |
|
|
12 | (4) |
|
2 Existing Precision Medicine Initiatives |
|
|
16 | (10) |
|
|
16 | (4) |
|
United Kingdom: 100,000 Genomes, 18 France: The French Plan for Genomic Medicine |
|
|
20 | (2) |
|
Japan: Initiative on Rare and Undiagnosed Diseases |
|
|
22 | (1) |
|
World Economic Forum: Center for the Fourth Industrial Revolution |
|
|
23 | (3) |
|
3 The Promise and Perils of Animal Models |
|
|
26 | (25) |
|
|
27 | (9) |
|
Introduction to Model Organisms |
|
|
27 | (2) |
|
International Mouse Phenotyping Consortium |
|
|
29 | (1) |
|
|
30 | (2) |
|
|
32 | (4) |
|
Unique Animal-Based Approaches |
|
|
36 | (10) |
|
|
36 | (1) |
|
|
37 | (3) |
|
Mouse Hospital Co-Clinical Trials |
|
|
40 | (3) |
|
Pets with Naturally Occurring Tumors |
|
|
43 | (3) |
|
Challenges of Using Animal Models for Precision Medicine |
|
|
46 | (5) |
|
|
46 | (2) |
|
The Animal Rule and Appropriate Modeling |
|
|
48 | (3) |
|
4 Reproducibility and Predictivity |
|
|
51 | (10) |
|
Translational Stroke Research: The "Worst Practices" of Animal Research |
|
|
52 | (1) |
|
|
53 | (3) |
|
Reproducibility in Large Shared Datasets |
|
|
56 | (2) |
|
The Paradoxes of Precision Medicine |
|
|
58 | (3) |
|
5 In Vitro Alternatives To Animal Models |
|
|
61 | (8) |
|
iPSCs to Model Chemotherapy-Induced Cardiotoxicity |
|
|
61 | (2) |
|
In Vitro Cardiac Disease Models |
|
|
63 | (1) |
|
Human Microphysiological Systems |
|
|
64 | (2) |
|
|
65 | (1) |
|
|
65 | (1) |
|
Quantitative Systems Pharmacology and Microphysiological Systems |
|
|
66 | (3) |
|
Human Microphysiological Systems |
|
|
67 | (2) |
|
6 Assessing Safety and Toxicology |
|
|
69 | (13) |
|
Patient Susceptibilities in Preclinical Drug Safety Assessment |
|
|
69 | (2) |
|
|
71 | (1) |
|
|
71 | (1) |
|
Co-expressed Gene Network Analysis as a Bridge for Extrapolation Between Species |
|
|
71 | (3) |
|
Using Genetically Diverse Mice to Test Susceptibility to Toxins |
|
|
74 | (2) |
|
To Identify Specific Polymorphisms Associated with Xenobiotic Toxicity |
|
|
75 | (1) |
|
To Evaluate Biomarker Performance Toward Assessing Human Clinical Adverse Outcomes |
|
|
76 | (1) |
|
As a Tool for Population-Based Estimates of Chemical Potency for Risk Assessment |
|
|
76 | (1) |
|
Integrating Evidence from Animal and Human Studies |
|
|
76 | (6) |
|
|
82 | (5) |
|
Personalized Medicine Coalition |
|
|
82 | (2) |
|
|
84 | (3) |
|
8 Reflections on the Workshop |
|
|
87 | (3) |
|
|
90 | (5) |
|
|
|
|
95 | (8) |
|
B Planning Committee Biographies |
|
|
103 | (5) |
|
|
108 | |